{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T06:50:08Z","timestamp":1787208608520,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002975","name":"dainippon sumitomo pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s12185-021-03263-y","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T12:02:43Z","timestamp":1637928163000},"page":"391-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4171-2162","authenticated-orcid":false,"given":"Momoko","family":"Nishikori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Takahara-Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisei","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"issue":"5","key":"3263_CR1","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.bbmt.2011.09.009","volume":"18","author":"E Jantunen","year":"2012","unstructured":"Jantunen E, Sureda A. The evolving role of stem cell transplants in lymphomas. Biol Blood Marrow Transplant. 2012;18(5):660\u201373.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"3263_CR2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/CCO.0000000000000403","volume":"29","author":"K Benekou","year":"2017","unstructured":"Benekou K, Montoto S. Role of stem cell transplant in lymphoma in the era of new drugs. Curr Opin Oncol. 2017;29(6):455\u20139.","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"3263_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","volume":"12","author":"U Zahid","year":"2017","unstructured":"Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Riaz IB, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12(3):217\u201326.","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"3263_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/ctrv.2000.0170","volume":"26","author":"MJ Maanen","year":"2000","unstructured":"Maanen MJ, Smeets CJ, Beijnen JH. Chemistry, pharmacology and pharmacokinetics of N, N\u2019, N\" -triethylenethiophosphoramide (ThioTEPA). Cancer Treat Rev. 2000;26(4):257\u201368.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"3263_CR5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00280-019-03914-2","volume":"84","author":"E Kondo","year":"2019","unstructured":"Kondo E, Ikeda T, Goto H, Nishikori M, Maeda N, Matsumoto K, et al. Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma. Cancer Chemother Pharmacol. 2019;84(4):849\u201360.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3263_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/1097-0142(19930701)72:1<271::AID-CNCR2820720147>3.0.CO;2-K","volume":"72","author":"RL Heideman","year":"1993","unstructured":"Heideman RL, Packer RJ, Reaman GH, Allen JC, Lange B, Horowitz ME, et al. A phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer. 1993;72(1):271\u20135.","journal-title":"Cancer"},{"key":"3263_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4137\/CMO.S7752","volume":"6","author":"P Prodduturi","year":"2012","unstructured":"Prodduturi P, Bierman PJ. Current and emerging pharmacotherapies for primary CNS lymphoma. Clin Med Insights Oncol. 2012;6:219\u201331.","journal-title":"Clin Med Insights Oncol"},{"issue":"5","key":"3263_CR8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1001\/archinte.1953.00240230028004","volume":"92","author":"H Shay","year":"1953","unstructured":"Shay H, Zarafonetis C, Smith N, Woldow I, Sun DC. Treatment of leukemia with triethylene thiophosphoramide (thio-TEPA); preliminary results in experimental and clinical leukemia. AMA Arch Intern Med. 1953;92(5):628\u201345.","journal-title":"AMA Arch Intern Med"},{"issue":"3","key":"3263_CR9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/1097-0142(1955)8:3<498::AID-CNCR2820080310>3.0.CO;2-M","volume":"8","author":"H Shay","year":"1955","unstructured":"Shay H, Sun DC. Clinical studies of triethylenethiophosphoramide in the treatment of inoperable cancer. Cancer. 1955;8(3):498\u2013511.","journal-title":"Cancer"},{"issue":"5","key":"3263_CR10","first-page":"510","volume":"61","author":"E Kondo","year":"2020","unstructured":"Kondo E. Primary central nervous system lymphoma: advances in treatment strategies. Rinsho Ketsueki. 2020;61(5):510\u20139 (In Japanese).","journal-title":"Rinsho Ketsueki"},{"issue":"suppl 7","key":"3263_CR11","first-page":"vii106","volume":"26","author":"R Suzuki","year":"2015","unstructured":"Suzuki R, Takahashi Y, Inoue M, Kanamori H, Hashii Y, Sakamaki H, et al. Thiotepa for autologous hematopoietic stem cell transplantation for solid tumors. Ann Oncol. 2015;26(suppl 7):vii106\u201351.","journal-title":"Ann Oncol"},{"key":"3263_CR12","unstructured":"TEPADINA 15 mg powder for concentrate for solution for infusion (summary of product characteristics). ADIENNE S.r.l. S.U, Caponago, Italy; 2015. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tepadina-epar-product-information_en.pdf. Accessed 19 June 2021."},{"key":"3263_CR13","unstructured":"Thiotepa 100 mg (RETHIO IV infusion) [Japanese package insert]. Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan; 2020. https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00068017.pdf. Accessed 19 June 19 2021."},{"issue":"5","key":"3263_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.bbmt.2008.12.489","volume":"15","author":"SO Ciurea","year":"2009","unstructured":"Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(5):523\u201336.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"3263_CR15","first-page":"303","volume":"5","author":"D Du Bois","year":"1989","unstructured":"Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Nutrition. 1989;5(5):303\u201311.","journal-title":"Nutrition"},{"issue":"3","key":"3263_CR16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","volume":"22","author":"JH Dalle","year":"2016","unstructured":"Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22(3):400\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"3263_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s12185-020-03007-4","volume":"112","author":"F Wada","year":"2020","unstructured":"Wada F, Nishikori M, Hishizawa M, Watanabe M, Aiba A, Kitano T, et al. Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation. Int J Hematol. 2020;112(5):609\u201313.","journal-title":"Int J Hematol"},{"issue":"9","key":"3263_CR18","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/blood.V91.9.3509","volume":"91","author":"SH Bernstein","year":"1998","unstructured":"Bernstein SH, Nademanee AP, Vose JM, Tricot G, Fay JW, Negrin RS, et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood. 1998;91(9):3509\u201317.","journal-title":"Blood"},{"issue":"S1","key":"3263_CR19","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.5045\/br.2020.S010","volume":"55","author":"YS Choi","year":"2020","unstructured":"Choi YS. Recent advances in the management of primary central nervous system lymphoma. Blood Res. 2020;55(S1):S58\u201362.","journal-title":"Blood Res"},{"issue":"5","key":"3263_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00277-010-1104-0","volume":"90","author":"SJ Kim","year":"2011","unstructured":"Kim SJ, Oh SY, Kim JS, Kim H, Lee GW, Won JH, et al. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. Ann Hematol. 2011;90(5):539\u201346.","journal-title":"Ann Hematol"},{"issue":"10","key":"3263_CR21","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1093\/annonc\/mdx515","volume":"28","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM. Secondary CNS lymphoma: the poisoned needle in the haystack. Ann Oncol. 2017;28(10):2335\u20137.","journal-title":"Ann Oncol"},{"issue":"3","key":"3263_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/ccr3.66","volume":"2","author":"SA van Blydenstein","year":"2014","unstructured":"van Blydenstein SA, Patel M, Philip V, Lakha A, Pather S, Westgarth-Taylor T, et al. Classical Hodgkin lymphoma involving the central nervous system (brain)\u2014an unusual presentation. Clin Case Rep. 2014;2(3):88\u201392.","journal-title":"Clin Case Rep"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03263-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03263-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03263-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T23:16:42Z","timestamp":1744154202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03263-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,26]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["3263"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03263-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,26]]},"assertion":[{"value":"16 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YM has received research grants from Kyowa Kirin Pharma, Astellas Pharma, Eisai Pharma, Ono Pharma, Pfizer Pharma, Asahi Kasei Pharma, MSD Pharma, Daiichi-Sankyo Pharma, Taisho Pharma, Taiho Pharma, Takeda Pharma, Chugai Pharma, Teijin Pharma, Nippon Kayaku, and Mochida Pharma, outside the submitted work. MT and SS are employees of Sumitomo Dainippon Pharma Co., Ltd. EK received honoraria from Sumitomo Dainippon Pharma and Otsuka. MN, NF, TI, have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}